Advertisement
Advertisement

NMRA

NMRA logo

Neumora Therapeutics, Inc. Common Stock

1.66
USD
Sponsored
-0.14
-7.54%
Jan 02, 15:59 UTC -5
Closed
exchange

Pre-Market

1.70

+0.04
+2.65%

NMRA Earnings Reports

Positive Surprise Ratio

NMRA beat 5 of 9 last estimates.

56%

Next Report

Date of Next Report
Apr 27, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.33
Implied change from Q3 25 (Revenue/ EPS)
--
/
+3.13%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-10.81%

Neumora Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, NMRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 5.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an increase of 3.13% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
logo
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
For Q3 2025, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 5.99%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.53%, changed from $2.62 before the earnings release to $2.58 the day after.
The next earning report is scheduled for Apr 27, 2026.
Based on 10 analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement